Hyamedix is a leading brand specializing in drug delivery and drug release profiles to enhance the safety and efficacy of medications. They utilize a unique, patented hydrogel technology that leverages the power of Hyaluronan (HA), a naturally occurring molecule in the human body. With their expertise, they develop custom drug products by combining hydrogel formulations with selected APIs for novel clinical needs.

The hydrogel technology developed by Hyamedix allows for optimal release and delivery of APIs, resulting in improved safety, efficacy, and patient compliance. By optimizing existing APIs and repurposing them, they can target new therapeutic spaces and offer cost-effective clinical pathways. Hyamedix has an impressive pipeline of projects at various stages of development, including treatments for osteoarthritis, COVID therapeutics, and nerve protection.

Through their joint ventures and collaborations, they are actively present in three different therapeutic spaces, working towards groundbreaking solutions. The brand is led by a highly experienced executive management team with deep knowledge in the biotechnology sector and Hyaluronic Acid production. They are driven by innovation and seeking partnerships with compounds that require improved drug delivery platforms.

Stay up to date with Hyamedix's latest developments and exciting projects by visiting their website and reading their press releases